Clinical Trial

Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone

Study acronym: GISCO
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The GISCO study plans to determine whether 8-week therapy is just as effective as 26-week cortisone therapy for treating giant cell arteritis * with tocilizumab, * while using less cortisone.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-12; most recent amendment 2026-04-30.
Trial Details
NCT Number NCT06833411
Lead Sponsor Insel Gruppe AG, University Hospital Bern
Conditions Giant Cell Arteritis (GCA)
Enrollment 178 participants
Start Date 2026-07
Primary Completion 2030-08 (estimated)
Study Completion 2032-08 (estimated)
Updated on ClinicalTrials.gov 2026-05-01